Fig. 1: Examples of validation for surrogate endpoints.
From: Surrogate endpoints in mature B-cell neoplasms – meaningful or misleading?
A End of treatment MRD status shows a correlation with overall survival on a patient-level, i.e. it has significant prognostic value. B The odds ratio of reaching undetectable MRD across multiple trials is strongly associated with the hazard ratios of PFS, i.e. trial-level correlation. Figure adapted from End Point Surrogacy in First-Line Chronic Lymphocytic Leukemia. Florian Simon et al., JCO 0, JCO.24.01192 [22]. Printed with permission.
